IFNL4 polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients

The aim of this study was to examine association between IFNL4 gene ss469415590 and treatment efficiency in group of Ukrainian PEG-interferon/ribavirin-treated chronic hepatitis C patients. Study group consisted of 92 unrelated hepatitis C virus genotype 1 mono-infected patients: case group–29 patie...

Full description

Saved in:
Bibliographic Details
Published inCytology and genetics Vol. 50; no. 5; pp. 330 - 333
Main Authors Kucherenko, A. M., Pampukha, V. M., Romanchuk, K. Yu, Chernushyn, S. Yu, Bobrova, I. A., Moroz, L. V., Livshits, L. A.
Format Journal Article
LanguageEnglish
Published New York Allerton Press 2016
Springer Nature B.V
Subjects
Biomedical and Life Sciences
Biomedicine
Hepatitis C
Human Genetics
Mutation
Patients
Polymorphism
pharmacogenetic marker
hepatitis C
treatment efficiency
IFNL4
Online AccessGet full text

Cover

More Information
Summary:The aim of this study was to examine association between IFNL4 gene ss469415590 and treatment efficiency in group of Ukrainian PEG-interferon/ribavirin-treated chronic hepatitis C patients. Study group consisted of 92 unrelated hepatitis C virus genotype 1 mono-infected patients: case group–29 patients with late or absent virological response; control group–63 patients with sustained virological response. Study material was genomic DNA. Genotyping was performed using amplification-refractory mutation system PCR. Statistical analysis was performed using GenePop and OpenEpi statistical packages. Obtained results show that ss469415590 Δ G /Δ G genotype is associated with poor virological response (OR = 3.62; CI 95%: 1.12–11.67) in PEG-interferon/ribavirin-treated chronic hepatitis C patients from Ukraine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0095-4527
1934-9440
DOI:10.3103/S0095452716050066